Federal Register / Vol. 70, No. 186 / Tuesday, September 27, 2005 / Notices 56477 

Imaging With Positron-Emitting 

Taxanes as a Guide to Antitumor 

Therapy 

Jerry M. Collins, Raymond W. Klecker, 

Lawrence Anderson (FDA) 

U.S. Provisional Application No. 60/ 

155,061 filed 21 Sep 1999 (HHS 

Reference No. E–263–1998/0–US–01); 

U.S. Patent Application Nos. 10/ 

088,561 filed 19 Mar 2002 (HHS 

Reference No. E–263–1998/0–US–03) 

and 10/319,812 filed 16 Dec 2002 

(HHS Reference No. E–263–1998/1–

US–01) are pending. 

Licensing Contact: Michael Shmilovich; 

(301) 435–5019; 

shmilovm@mail.nih.gov. 

Available for licensing and 

commercial development is a method 

for using positron-emitting compounds 

to label taxane type drugs. This 

invention also describes methods of 

synthesizing these taxane type 

compounds. Further, methods to guide 

treatment of solid tumors, with labeled 

taxanes, are also disclosed in the 

present application. Advantages of 

using this technology include: (1) 

Avoidance of exposing patients to toxic 

drugs that have no potential for benefit; 

(2) ability to rapidly determine whether 

a given tumor will be likely to respond 

to a particular drug; and (3) the ability 

to monitor the impact of various 

dosages, schedules, and modulators for 

delivery, in situ, at the actual tumor 

under treatment conditions. 

Additional information may be found 

in: Ravert et al., ‘‘Radiosynthesis of 

[ 11C]paclitaxel,’’ J Label Compd and 

Radiopharm, 2002, 45(6):471–477. 

Dated: September 15, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 05–19173 Filed 9–26–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Small 

Grants Program for Cancer Epidemiology and 

Cancer Research Small Grant Program. 

Date: November 8–10, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel & Executive 

Meeting Center, 1750 Rockville Pike, 

Regency Meeting Room, Rockville, MD 

20852. 

Contact Person: Mary Jane Slesinski, PhD, 

Scientific Review Administrator, Special 

Review and Resources Branch, DEA/NCI/ 

NIH, 6116 Executive Boulevard, Room 8045, 

Bethesda, MD 20892, 301/594–1566, 

slesinsm@mail.nih.gov 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 16, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–19178 Filed 9–26–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

President’s Cancer Panel. 

The meeting will be open to the pubic 

as indicated below, with attendance 

limited to space available. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

Name of Committee: President’s Cancer 

Panel. 

Date: October 24, 2005. 

Open: October 24, 2005, 8 a.m. to 5 p.m. 

Agenda: Strategic Planning-Translating 

Research Team Science/Clinical Research/ 

Infrastructure Needs. 

Place: Hotel Washington, 15th and 

Pennsylvania Ave., NW., Washington, DC 

20004. 

Contact Person: Abby Sandler, PhD, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 

Building 6116, Room 212, 6116 Executive 

Boulevard, Bethesda, MD 20892, 301–451–

9399. 

Any interested person may file written 

comments with the committee by forwarding 

the comments to the Contact Person listed on 

this notice. The comments should include 

the name, address, telephone number and, 

when applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/pcp/pcp.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 16, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–19179 Filed 9–26–05; 8:45am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the public in 

accordance with the provisions set forth 

in sections 552b(c)(4) and 552b(c)(6), 

Title 5 U.S.C., as amended. The contract 

proposals and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the contract proposals, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Clinical 

Trial Data Collection Using Handheld 

Technology. 

Date: October 12, 2005.